psa

The FDA's proposed narrowing of the testosterone therapy prostate cancer contraindication to metastatic disease only reflects current clinical evidence, opening the door to testosterone therapy in appropriately selected men with treated localized prostate cancer or on active surveillance, with...

I've recently added HCG 500ui twice a week to my protocol. I'm on TRT 50mg EOD. My PSA went from 1.6 to 2.6 after adding the HCG. Any cause for concern?

Another one under the belt for Dr. Bhasin! https://edhub.ama-assn.org/jn-learning/audio-player/19061825 Interview with Shalender Bhasin, MBBS, author of Testosterone Treatment in Prostate Cancer Survivors With Hypogonadism: A Randomized Clinical Trial, and Peter C. Albertsen, MD, author...

Explore the definitive findings of the "European Study of Prostate Cancer Screening — 23-Year Follow-up" to understand how long-term prostate cancer screening significantly impacts patient survival. Maurie Markman, MD, provides a detailed analysis of this landmark study, highlighting a 13%...

This expert panel discussion at the Southwest Prostate Cancer Symposium explores how prostate cancer screening and diagnostic decisions are made in real clinical practice. The conversation begins by discussing historical prostate-specific antigen (PSA) thresholds and why PSA alone is...

Dr. Neal Shore https://www.urotoday.com/video-lectures/asco-gu-2026/video/5448-psa-control-after-treatment-suspension-embark-data-at-36-months-neal-shore.html Neal Shore discusses EMBARK trial exceptional responders who maintained PSA below 0.2 for approximately three years while recovering...

08:00 What Happens After an Elevated PSA In this episode, Dr. Rena Malik, MD and Dr. Scott Eggener explore the complexities of prostate cancer screening, discussing personalized risk assessment, PSA testing, and the evolving guidelines on when to start and stop screening. They break down...

Prostate Cancer Detection Statistics In the United States, approximately 333,830 men receive new prostate cancer diagnoses annually, with around 36,320 deaths from the disease. Early detection is critical to prevent identifying cancer at advanced stages, which worsens outcomes. Traditional...

Chapters 1:18 What are the implications of the NEJM's new paper on PSA? 5:28 At what age should most men be getting their PSA checked? 7:56 What is the usual "next step" following a high PSA reading? 10:52 What exactly does a high PSA signify? Does it always mean cancer? 14:24 Alex's conclusions

Is the biopsy needle more dangerous than the cancer itself? In this episode, Dr. Geo sits down with Dr. Mark Emberton, Dean of Medical Sciences at UCL and a global leader in urologic oncology. We dive deep into the "See and Treat" revolution—a massive shift in prostate cancer care that moves...

In this special Urology on the Beach edition of Pearls and Perspectives, host Amy Pearlman, MD, sits down with Mark L. Gonzalgo, MD, PhD, MBA, to discuss his recent appointment as chair of the Department of Urology at the University of Miami and his vision for leading a large academic urology...

In this episode, Dr. Brandon & Dr. Morgentaler talk about the emerging evidence that testosterone therapy may be safe—and even beneficial—for men with metastatic prostate cancer. Chapters 00:11 – Testosterone Use in Metastatic Prostate Cancer Dr. Morgentaler introduces the surprising...

* Dr. Carlsson asserts that prostate cancer screening is moving toward integrated, risk-adapted models, combining PSA, biomarkers, imaging, and AI to optimize outcomes for men globally. Dr. Sigrid Carlsson, MD, PhD, MPH, Head, Division of Clinical Epidemiology of Early Cancer Detection...

Prostate Cancer What's new and What's coming by Dr. Fred Saad, CQ, MD, FRCS, FCAHS, Professor and Chairman of the Department of Surgery at the University de Montreal, Holder of the Raymond Garneau Chair in Prostate Cancer Research, Director of GU Oncology and Clinical Research as well as the...

Are we entering a new era of prostate cancer testing? In this episode, Dr. Geo speaks with Dr. Jeffrey Tosoian—urologist, researcher, and lead author behind MyProstateScore 2.0 (MPS 2.0)—a cutting-edge urine test that may outperform PSA and even MRI in identifying clinically significant prostate...

In this episode of the Dr. Geo Prostate Podcast, Dr. Geo unpacks President Joe Biden’s recent diagnosis of Gleason 9 advanced prostate cancer. With real talk and real science, Dr. Geo dives deep into what this diagnosis means medically, why it’s raising eyebrows, and how it could have been...

In this episode, Dr. Morgentaler and Dr. Brandon unpack the myth that eunuchs never get prostate cancer and reveal how powerful stories—not science—shaped decades of medical belief about testosterone. 00:07 – The Story of Testosterone and Prostate Cancer In this episode, Dr. Morgentaler...

Chapters 0:26 What is micro-ultrasound and how does it work? 3:09 How well does micro-ultrasound compare to 3T MRI's? 4:57 How well does micro-ultrasound compare to PSMA-PET scans? 6:03 How does micro-ultrasound fit into the realm of biopsies for prostate cancer? 7:38 Is there a chance...

Prostate Biopsy by Dr. Takeshi Namekawa, Uro-Oncology Fellow, Department of Urologic Sciences, UBC

Introduction Men remain at risk for prostate cancer after simple prostatectomy. Despite our understanding of this, no parameters exist to inform urologists of prostate specific antigen (PSA) monitoring after surgery. This study aimed to compare initial postoperative PSA measurements and PSA...

Adam B. Murphy, MD, discusses the Stockholm3 blood test, which determines prostate cancer risk and may help reduce unnecessary prostate biopsies. Dr. Murphy and colleagues aimed to find out whether this blood test could improve prostate cancer detection in patients from diverse groups in the...

* Interestingly, when analyzing our data by individual patients, 16% exhibited an elevated PSA (≥1 ng/mL) throughout the one-year period. These patients had a median (IQR) baseline PSA of 3.5 (1.8–5.5) ng/mL, which was higher compared to the overall cohort. Notably, three of these patients...

https://bmjoncology.bmj.com/content/4/1/e000520 The main findings of the study on prostate cancer risk in men with testosterone deficiency (TD) and a family history of prostate cancer (PCa) receiving testosterone therapy (TTh) are: - **Prostate Cancer Risk:** There was no significant...

Prostate cancer screening is an essential aspect of men’s health, and current advancements in testing are making early detection more precise than ever before. While the PSA (Prostate-Specific Antigen) test has long been the standard, it has limitations and may lead to unnecessary biopsies. The...

Andrew Vickers, PhD, Professor of Healthcare Policy and Research at Weill Cornell Medical College and member of the Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics in New York, NY, delivers a nine-minute presentation on the need for reforming the Gleason...

Cureus . 2024 Dec 2;16(12):e74959. doi: 10.7759/cureus.74959. eCollection 2024 Dec. Association of Vitamin D and Prostate Health Status in Men: An Analytical Cross-Sectional Study Janvitha Reddy 1, Arul Senghor K A 1, Vinodhini V M 1, N Prasath 2, Mansi Ravat 3 Affiliations Expand PMID...

* TTh can be given to select men after RP. Longer term outcome needs to be assessed. Purpose Testosterone therapy (TTh) in men with T deficiency who have undergone radical prostatectomy (RP) for prostate cancer remains controversial. We aimed to assess the impact of TTh on biochemical...

* Approximately 39% of PCPs were not aware of the suppressive effects of 5-ARIs on PSA and 63.5% were not sure or incorrectly answered when asked about calculating the corrected PSA of a patient who is taking 5-ARIs. Furthermore, nearly 80% were not sure or would not refer a patient who is...

Chapters 0:49 What is the MiPS2 test and how does it work? 2:14 Can urine tests be used as a partial substitute for biopsies? 4:52 How does the 95% accuracy rate of urine tests affect the screening process? 7:17 What percentage of cancer is missed by different screening methods? 9:25 Can a...